Dublin, Ireland, 21 October 2021 – Orphan Drug Consulting Celebrates its Fourth Anniversary.

Orphan Drug Consulting is proud to announce the celebration of 4 years in business. Since its establishment in 2017, Orphan Drug Consulting has grown from a core team based in Ireland to a global group with offices in Dublin, London, and Boston partnering with over 30 companies across the world to provide best-in-class support to the industry and a combined experience of launching products into over 100 countries in Europe, North America, LATAM and APAC.

Orphan Drug Consulting’s unique blend of industry-leading expertise across multiple functional areas, backed by an experienced and holistically focused management team, has enabled clients to have a deeper understanding of their organizational and function-specific requirements as they approach and launch into new markets. Adopting a cross-functional and integrative approach, the team has successfully led companies through their launch strategy development, implementation, and maintenance post-launch, driving functional excellence across the areas of finance and entity structuring, supply chain, quality assurance, customs/VAT, human resources, and organizational development, vendor management, and regulatory affairs/pharmacovigilance.

 

ODC 4 Years

 

Evelyn Kelly, Chief Executive Officer and Founder of Orphan Drug Consulting commented – “It has been a privilege to work closely with such a talented group and the exceptional growth of the company is a testament to the ODC team and the strong values they embody daily. As we continue to grow, the team is committed to delivering this industry-leading expertise to new and existing clients. We’re seeing more research and development in rare diseases and growth in the number of approvals each year and we are excited to be part of this continued growth. It has been an incredible journey and we are proud to celebrate four years of Orphan Drug Consulting. We look forward to continuing our work with clients focused on underserved patient populations around the world as we continue to expand our services into new markets globally.”

Jason Cameron, Chief Operating Officer of Orphan Drug Consulting adds – “I’m grateful to be a part of the expert team here at Orphan Drug Consulting. In the past, I’ve been fortunate to work in companies at all different stages of the product lifecycle, and having a company like Orphan Drug Consulting can add huge value to organizations looking to commercialize and launch new products. I have watched this company grow its skilled workforce of subject matter experts and expand its services to best match the needs of its clients. I’m excited to see the future of Orphan Drug Consulting and look forward to continuing to reach important milestones each year, both for and with our clients.”

ENDS

For more information contact [email protected] or visit www.orphandrugconsulting.com.

Contact Us Now